Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer

Real‐world utilization of PD‐1/PD‐L1 inhibitors with palliative radiotherapy in patients with metastatic non‐small cell lung cancer

Abstract Background Programmed cell death protein 1 (PD‐1) blockade plus radiotherapy may be a promising strategy to improve the prognosis of patients with metastatic non‐small cell lung cancer (NSCLC). However, the optimum combined scheme, treatment time of radiotherapy, and irradiated lesion have...

Full description

Bibliographic Details
Main Authors:	Zi‐Chao Zhou, Kai‐Yan Chen, Na Li, Ming‐Ying Xie, Jia‐Min Sheng, Yun Fan, Zhi‐Yu Huang
Format:	Article
Language:	English
Published:	Wiley 2022-08-01
Series:	Thoracic Cancer
Subjects:	immunotherapy non‐small cell lung cancer radiotherapy
Online Access:	https://doi.org/10.1111/1759-7714.14553

Similar Items

Radiotherapy combined with PD‐1/PD‐L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges
by: Zi‐Ying Chen, et al.
Published: (2023-01-01)

Safety of PD-1/PD-L1 Inhibitors Combined With Palliative Radiotherapy and Anti-Angiogenic Therapy in Advanced Hepatocellular Carcinoma
by: Liting Zhong, et al.
Published: (2021-05-01)

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
by: Lu Wen, et al.
Published: (2021-12-01)

PD‐L1 inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real‐world evidence
by: Litang Huang, et al.
Published: (2024-04-01)

Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma
by: Jing Lin, et al.
Published: (2022-07-01)

Prospective Evaluation of All-lesion Versus Single-lesion Radiotherapy in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors
by: Philipp Schubert, et al.
Published: (2020-10-01)

Toxicity Profile of Combining PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy in Non-Small Cell Lung Cancer: A Systematic Review
by: Butuo Li, et al.
Published: (2021-03-01)

PD-1 inhibitor combined with radiotherapy and GM-CSF in MSS/pMMR metastatic colon cancer: a case report
by: Jiabao Yang, et al.
Published: (2023-04-01)

Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma
by: Tiesuo Zhao, et al.
Published: (2024-03-01)

Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
by: Ze-Long Liu, et al.
Published: (2020-08-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
by: Mathieu Grapin, et al.
Published: (2019-06-01)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
by: Hongge Liang, et al.
Published: (2020-04-01)

Anti-PD-1 antibody in combination with radiotherapy as first-line therapy for unresectable intrahepatic cholangiocarcinoma
by: Meiyan Zhu, et al.
Published: (2024-04-01)

Optimizing the Treatment Schedule of Radiotherapy Combined With Anti-PD-1/PD-L1 Immunotherapy in Metastatic Cancers
by: Yuehong Kong, et al.
Published: (2021-03-01)

Safety and Efficacy of PD‐1/PD‐L1 inhibitors combined with radiotherapy in patients with non‐small‐cell lung cancer: a systematic review and meta‐analysis
by: Yichao Geng, et al.
Published: (2021-02-01)

Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy  in Elderly Patients with Advanced NSCLC
by: Yunye MAO, et al.
Published: (2024-05-01)

Efficacy and safety of anti-PD-1 inhibitor versus anti-PD-L1 inhibitor in first-line treatment of extensive-stage small cell lung cancer: a multicenter retrospective study
by: Boyu Qin, et al.
Published: (2024-01-01)

Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy
by: T. Finazzi, et al.
Published: (2018-04-01)

High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer
by: Hui‐Bo Feng, et al.
Published: (2021-10-01)

Hyperprogressive disease after radiotherapy combined with anti-PD-1 therapy in renal cell carcinoma: a case report and review of the literature
by: Chao Liu, et al.
Published: (2021-03-01)

Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma
by: Lukas W. Pfannenstiel, et al.
Published: (2019-01-01)

PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review
by: Chun-Xu Liao, et al.
Published: (2023-09-01)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
by: Anissa Roger, et al.
Published: (2018-07-01)

Blocking interaction between SHP2 and PD‐1 denotes a novel opportunity for developing PD‐1 inhibitors
by: Zhenzhen Fan, et al.
Published: (2020-05-01)

Real-world outcomes of PD-L1 inhibitors combined with thoracic radiotherapy in the first-line treatment of extensive stage small cell lung cancer
by: Jianfeng Peng, et al.
Published: (2023-07-01)

Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
by: Zhong L, et al.
Published: (2025-01-01)

Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
by: André F. Oliveira, et al.
Published: (2019-05-01)

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review
by: Yan Z, et al.
Published: (2020-07-01)

Small molecule inhibitors against PD-1/PD-L1 immune checkpoints and current methodologies for their development: a review
by: Chang Liu, et al.
Published: (2021-04-01)

Prognostic implication of PD‐L1 polymorphisms in non‐small cell lung cancer treated with radiotherapy
by: Min Kyu Kang, et al.
Published: (2021-11-01)

Hypofractionated radiotherapy combined with a PD-1 inhibitor, granulocyte macrophage-colony stimulating factor, and thymosin-α1 in advanced metastatic solid tumors: a multicenter Phase II clinical trial
by: Jiamin Yu, et al.
Published: (2025-02-01)

Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal Cancer
by: Liying Sun, et al.
Published: (2021-10-01)

Safety and Efficacy of Concurrent or Sequential Radiotherapy Plus (PD-1) Inhibitors in Oligometastatic Esophageal Cancer
by: Duan Y, et al.
Published: (2023-01-01)

Effect of radiotherapy on T cell and PD-1 / PD-L1 blocking therapy in tumor microenvironment
by: Chen Chen, et al.
Published: (2021-06-01)

Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO)
by: Pierluigi Bonomo, et al.
Published: (2018-02-01)

Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents
by: Chengliang Sun, et al.
Published: (2022-12-01)

Overcoming resistance to PD-1/PD-L1 inhibitors in esophageal cancer
by: Chao Cheng, et al.
Published: (2022-09-01)

Virtual Screening and In Vitro Evaluation of PD-L1 Dimer Stabilizers for Uncoupling PD-1/PD-L1 Interaction from Natural Products
by: Jrhau Lung, et al.
Published: (2020-11-01)

Case Report: Intervention of radiotherapy improves the prognosis of rectal squamous cell carcinoma with high PD-L1 expression and enable patients to obtain NED status
by: Fuyin Qu, et al.
Published: (2023-07-01)